J&J-New Data From Tar-200 Phase 2B Sunrise-1 Study Show 84% Complete Response Rate in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer
J&J-來自Tar-200第20億Sunrise-1研究的新數據顯示,在高風險非肌層侵襲性膀胱癌患者中,完全緩解率達到84%
J&J-New Data From Tar-200 Phase 2B Sunrise-1 Study Show 84% Complete Response Rate in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer
J&J-來自Tar-200第20億Sunrise-1研究的新數據顯示,在高風險非肌層侵襲性膀胱癌患者中,完全緩解率達到84%
譯文內容由第三人軟體翻譯。